The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

There is no known biomarker for follow-up of patients with sarcoidosis. Visfatin is a proinflammatory adipokine which has been studied for several inflammatory diseases such as diabetes mellitus, obesity and metabolic syndrome. Our aim was to evaluate visfatin together with inflammatory biomarkers like serum ACE, sedimentation and CRP.59 patients with sarcoidosis were included in our study. Serum concentrations of visfatin were analyzed by ELISA. Patients were divided into those with and without parenchymal involvement. Serum ACE levels and ESR were significantly higher in patients with pulmonary involvement. There was no association between CRP levels, serum visfatin concentration and parenchymal involvement.We think visfatin is not a useful biomarker for diagnosing and monitoring sarcoidosis. Comparison of sarcoidosis patients with/without parenchymal involvementWith parenchymal involvementWithout parenchymal involvementpCRP (mg/l)7.62±8.284.81 ±4.110.282Sedimentation (mm/hr)27.08 ±17.6719.81 ±7.690.043Serum ACE level (U/L)75.91 ± 54.8439.95 ± 23.920.002Serum visfatin level (ng/ml)30 ± 15.5128.90 ± 17.640.826
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Diffuse Parenchymal Lung Disease Source Type: research